- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bicycle Therapeutics Ltd (BCYC)
Bicycle Therapeutics Ltd stock price live, this page displays NASDAQ BCYC stock exchange data. View the BCYC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Bicycle Therapeutics Ltd real time stock price chart below.
What Is the Bicycle Therapeutics Ltd Stock Price Today?
The Bicycle Therapeutics Ltd stock price today is 7.08.
What Is the Stock Symbol for Bicycle Therapeutics Ltd?
The stock symbol for Bicycle Therapeutics Ltd is ""BCYC.""
What Stock Exchange Does Bicycle Therapeutics Ltd Trade On?
Bicycle Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Bicycle Therapeutics Ltd a Good Stock to Buy?
Determining whether Bicycle Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCYC quote. (ISIN: US0887861088)
What Is the Bicycle Therapeutics Ltd Stock Price Today?
The Bicycle Therapeutics Ltd stock price today is 7.08.
What Is the Stock Symbol for Bicycle Therapeutics Ltd?
The stock symbol for Bicycle Therapeutics Ltd is ""BCYC.""
What Stock Exchange Does Bicycle Therapeutics Ltd Trade On?
Bicycle Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Bicycle Therapeutics Ltd a Good Stock to Buy?
Determining whether Bicycle Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCYC quote. (ISIN: US0887861088)
Fair Value
An estimate of a Bicycle Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.01
7.26
52 wk Range
6.10
28.67
BCYC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BCYC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Bicycle Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.017.26
52 wk Range
6.1028.67
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCYC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Bicycle Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
23.91
Upside
+237.70%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell
Bicycle Therapeutics Ltd Company Profile
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics Ltd SWOT Analysis
Pipeline Progress | Explore Bicycle Therapeutics' advancing clinical trials, focusing on zelenectide pevedotin for metastatic urothelial cancer and other promising candidates |
Financial Fortitude | Delve into Bicycle's robust cash position of $792.9 million, providing runway into 2027 despite ongoing R&D investments and clinical expenses |
Market Positioning | Learn how Bicycle's innovative platform technology and competitive efficacy data position the company in the crowded oncology treatment landscape |
Analyst Outlook | Discover varied analyst perspectives, with price targets ranging from $13 to $48, reflecting both optimism and caution about Bicycle's future prospects |
Compare BCYC to Peers and Sector
Metrics to compare | BCYC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCYCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −2.3x | −0.6x | |
PEG Ratio | −0.31 | −0.06 | 0.00 | |
Price/Book | 0.7x | 2.2x | 2.6x | |
Price / LTM Sales | 25.4x | 7.1x | 3.3x | |
Upside (Analyst Target) | 242.9% | 380.8% | 39.1% | |
Fair Value Upside | Unlock | 14.5% | 5.4% | Unlock |
Analyst Ratings
10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 23.91
(+237.70% Upside)
Earnings
Latest Release
Aug 08, 2025
EPS / Forecast
-1.14 / -0.94
Revenue / Forecast
2.92M / 9.43M
People Also Watch
FAQ
What Stock Exchange Does Bicycle Therapeutics Trade On?
Bicycle Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Bicycle Therapeutics?
The stock symbol for Bicycle Therapeutics is "BCYC."
What Is the Bicycle Therapeutics Market Cap?
As of today, Bicycle Therapeutics market cap is 515.64M.
What Is Bicycle Therapeutics's Earnings Per Share (TTM)?
The Bicycle Therapeutics EPS (TTM) is -3.50.
When Is the Next Bicycle Therapeutics Earnings Date?
Bicycle Therapeutics will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is BCYC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Bicycle Therapeutics Stock Split?
Bicycle Therapeutics has split 0 times.
How Many Employees Does Bicycle Therapeutics Have?
Bicycle Therapeutics has 305 employees.
What is the current trading status of Bicycle Therapeutics (BCYC)?
As of 29 Aug 2025, Bicycle Therapeutics (BCYC) is trading at a price of 7.08, with a previous close of 7.00. The stock has fluctuated within a day range of 7.01 to 7.26, while its 52-week range spans from 6.10 to 28.67.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.